Back to top
more

Shockwave Medical Inc. (SWAV)

(Delayed Data from NSDQ)

$43.43 USD

43.43
437,633

+2.29 (5.57%)

Updated May 3, 2019 04:00 PM ET

After-Market: $43.32 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Is the Options Market Predicting a Spike in ShockWave Medical (SWAV) Stock?

by Zacks Equity Research

Investors need to pay close attention to ShockWave Medical (SWAV) stock based on the movements in the options market lately.

Should iShares Russell 2000 Growth ETF (IWO) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for IWO

Amedisys (AMED) Faces Macro Challenges, Margin Pressure

by Zacks Equity Research

The Contessa Health acquisition seems to be strategically aligned with Amedisys' (AMED) business.

Teleflex (TFX) OEM Arm Grows, Supply Issue Persists

by Zacks Equity Research

From a geographic perspective, Teleflex (TFX) is seeing strong results in Asia, which continues to be an important growth driver for Teleflex.

Here's Why Investors Should Retain Zimmer Biomet (ZBH) Now

by Zacks Equity Research

Investors are optimistic about Zimmer Biomet (ZBH) owing to ongoing business recovery from the COVID-led pandemic impact.

Globus Medical (GMED) Global Growth Strong Despite Margin Woe

by Zacks Equity Research

Despite continued margin declines in Japan, Globus Medical (GMED) remains positive on the progress and potential of its international business for long-term growth as it continues to reset the market in the country.

Syneos Health (SYNH) Hurt by Low Reimbursable Expense, FX Issue

by Zacks Equity Research

Syneos Health (SYNH) experiences delays in large pharma award decisions, with net awards being impacted by greater-than-normal delays.

3 Reasons to Retain Surmodics (SRDX) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Surmodics (SRDX) owing to its solid prospects in the thrombectomy business.

Neogen (NEOG) Rises 7.9% Since Q1 Earnings: What's Driving It?

by Zacks Equity Research

Investors are optimistic about Neogen's (NEOG) recent product launches and strong global presence.

3 Reasons to Retain Nevro (NVRO) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Nevro (NVRO), owing to its R&D edge.

Neogen (NEOG) Benefits From Advanced Portfolio, Global Growth

by Zacks Equity Research

Barring Australia and China, solid international operations also buoy optimism for Neogen (NEOG).

Here's Why You Should Retain Hologic (HOLX) Stock for Now

by Zacks Equity Research

Investors are optimistic about Hologic (HOLX), led by the continued strength of the GYN Surgical business.

3 Reasons to Retain Glaukos (GKOS) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Glaukos (GKOS) on the back of continued strength in its flagship iStent.

Here's Why You Should Retain Charles River (CRL) Stock Now

by Zacks Equity Research

Investors are optimistic about Charles River (CRL) on robust performances across the RMS and DSA segments.

Insulet's (PODD) Omnipod Sales Aid, Costs Continue to Rise

by Zacks Equity Research

Insulet (PODD) progresses well with respect to its four-pillar strategy, wherein the first two pillars include expanding access and awareness, and delivering consumer-focused innovation.

3 Reasons to Retain OPKO Health (OPK) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about OPKO Health (OPK) owing to its potential in RAYALDEE.

Abbott (ABT) to Upgrade PHCs Across India With New Pact

by Zacks Equity Research

Abbott's (ABT) HWC program is likely to benefit more than 2.5 million people from under-resourced communities annually.

Omnicell (OMCL) Ailed by Mounting Costs, Macroeconomic Issues

by Zacks Equity Research

Macroeconomic factors adversely affect bookings and revenues in Omnicell's (OMCL) point-of-care business. The company reduces its overall bookings and revenue outlook for the year.

Here's Why You Should Retain McKesson (MCK) Stock Right Now

by Zacks Equity Research

McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.

3 Reasons to Retain Inogen (INGN) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Inogen (INGN) on its potential in the POC space and a strong product portfolio.

SmileDirectClub (SDC) Gains From Innovation Amid Macro Issues

by Zacks Equity Research

A series of cutting-edge innovations, strategic distribution and insurance partnerships are added positives for SmileDirectClub (SDC).

Here's Why Investors Should Retain Thermo Fisher (TMO) Stock

by Zacks Equity Research

Investors are optimistic about Thermo Fisher's (TMO) continued strength across its certain end markets.

Here's Why You Should Retain Edwards Lifesciences (EW) Now

by Zacks Equity Research

Investors are optimistic about Edwards Lifesciences (EW), led by strong underlying growth across all product groups.

Should First Trust Mid Cap Growth AlphaDEX ETF (FNY) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for FNY

McKesson (MCK) Announces Availability of FDA-Accepted Drug

by Zacks Equity Research

The availability of FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients more treatment options for PEComa.